Drug Profile
Ixoberogene soroparvovec - Adverum Biotechnologies
Alternative Names: AAV.7m8-aflibercept; ADVM-022; Ixo-vecLatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Weill Cornell Medical College
- Developer Adverum Biotechnologies
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diabetic retinopathy; Wet age-related macular degeneration
- Discontinued Diabetic macular oedema
Most Recent Events
- 18 Mar 2024 Adverum Biotechnologies plans to meet US and EU regulatory bodies for phase-III trial for Wet age-related macular degeneration before H1 2025
- 18 Mar 2024 Efficacy and adverse events data from phase-I OPTIC trial in Wet age-related macular degeneration released by Adverum Biotechnologies
- 18 Mar 2024 Adverum Biotechnologies plans a phase III trial for Wet age-related macular degeneration in the US and EU in 1H of 2025